CI-966

CI-966 is an experimental drug that has been studied for its potential effects on the central nervous system. It is classified as a GABA reuptake inhibitor, which means it inhibits the reuptake of gamma-aminobutyric acid (GABA), a key inhibitory neurotransmitter in the brain.

Mechanism of Action

CI-966 works by inhibiting the reuptake of GABA into neurons and glial cells, thereby increasing the levels of GABA in the synaptic cleft. This action enhances the inhibitory effects of GABA, which can lead to a reduction in neural excitability and has potential therapeutic effects for conditions such as epilepsy and anxiety disorders.

Potential Therapeutic Uses

Research has suggested that CI-966 may be useful in the treatment of various neurological disorders, including:

• Epilepsy
• Anxiety disorders
• Depression
• Schizophrenia

Side Effects

As an experimental drug, the side effects of CI-966 are not fully understood. However, potential side effects may include:

• Drowsiness
• Dizziness
• Nausea
• Headache

Research and Development

CI-966 is still under investigation, and more research is needed to fully understand its efficacy and safety profile. Clinical trials are ongoing to determine its potential benefits and risks in treating various neurological conditions.

See Also

• GABA reuptake inhibitor
• Neurotransmitter
• Epilepsy
• Anxiety disorder

References

‎